Method for uses of proinsulin transferrin fusion proteins as prodrugs
The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target cells via the endocytotic pathway, such as transferrin. The protein precursor is a prohormone or a profactor, such as proinsulin. Methods of this invention include the steps of selecting a protein suitable as the delivery domain, constructing a vector to encode the fusion protein, and expressing the fusion protein in a suitable expression host. Also disclosed is a method for targeted-delivery of prodrugs to livers and a method of reducing hepatic glucose production.
1. A method of delivering a proinsulin protein to the liver of a subject, comprising:
administering by injection a proinsulin transferrin fusion protein to a subject in need thereof,
wherein said proinsulin transferrin fusion protein comprises a preproinsulin sequence linked to a transferrin (Tf) sequence via a linker sequence, wherein the linker sequence consists of a leucine-glutamate dipeptide linker sequence, and
wherein the proinsulin transferrin protein is delivered to the liver in an amount effective to produce a normoglycemic level relative to a phosphate buffered saline (PBS) control at 12 hours post-injection under fasting conditions.
2. The method of claim 1 , wherein the effective amount of proinsulin transferrin fusion protein is an amount sufficient to reduce hepatic glucose production.
3. The method of claim 1 , wherein proinsulin transferrin fusion protein is administered in a single injection.
4. The method of claim 1 , wherein the proinsulin transferrin protein is delivered to the liver in an amount effective to reduce mRNA levels of glucose-6-phosphatase.
5. A method for reducing hepatic glucose production in a subject in need thereof, comprising:
administering by injection to said subject an effective amount of a proinsulin transferrin fusion protein,
wherein said proinsulin transferrin fusion protein comprises a preproinsulin sequence linked to a transferrin (Tf) sequence via a linker sequence, wherein the linker sequence consists of a leucine-glutamate dipeptide linker sequence, and
wherein the effective amount is sufficient to produce a normoglycemic level relative to a phosphate buffered saline (PBS) control at 12 hours post-injection under fasting conditions.
6. The method of claim 5 , wherein the effective amount is injected in a single injection.
7. The method of claim 5 , wherein the effective amount is an amount sufficient to reduce mRNA levels of glucose-6-phosphatase.
8. The method of claim 1 or claim 5 , wherein the injection is intravenous or subcutaneous.